Nature Reviews Drug Discovery

Papers
(The H4-Index of Nature Reviews Drug Discovery is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)
ArticleCitations
New target for anorexia2772
Alzheimer antibody rush begins, as efficacy concerns remain1484
Will psychedelics be ‘a revolution in psychiatry’?1479
Mechanism mediating methylenomycin production1082
Generating neurons in the adult brain932
First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential868
Upcoming market catalysts in Q3 2021805
New CAR’s bells and whistles795
Brain glucose mediates amphotericin B tolerance659
Acyl-lysine reader inhibitor blocks AML progression600
Identifying selective PI3KC2α inhibitors587
Putting a PIN in pancreatic cancer569
A cancer drug wish list532
FDA approves first-in-class NK3 receptor antagonist for hot flushes463
Hypoimmune iPSCs escape immune detection440
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?408
A spirulina-based biomanufacturing platform401
Small-molecule screens for targeting non-coding RNA392
Vertex’s NaV1.8 inhibitor passes phase II pain point376
Monoclonal antibody treats yellow fever370
DENV inhibitor effective in non-human primates356
Decrypting drug action at the level of PTMs355
PKN3: a target in cancer metastasis330
A new path to targeted protein degradation?316
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform312
Pandemic vaccines: a formidable challenge for pharmacovigilance310
Neurons give metastatic cells a push304
Apolipoprotein L2 inhibitor mitigates fibrosis289
RAS-targeted therapies287
Non-antibiotic drug network reveals new leads for antibiotics287
Kinase inhibitor rescues the liver281
AI serves up target and inhibitor for lung fibrosis280
FDA approves first complement factor D inhibitor277
Synthesizing portimines275
A ROS-mediated resistance pathway to anticancer drugs271
The importance of persistence in cancer drug development266
Novo Nordisk and GlaxoSmithKline buy into RNAi262
FDA approves first Friedreich’s ataxia drug254
Overcoming ICB resistance in lung cancer252
Allosteric adenosine receptor modulator alleviates pain242
Rediscovering hygromycin A for Lyme disease treatment232
Towards polio eradication217
Massive misuse of chemical probes undermines the utility of these tools198
Treating cannabis use disorder196
What’s next for an immuno-oncology powerhouse?194
Stalled molecular motor inhibits tumour growth193
Shifts in the clinical trial landscape191
The pipeline and market for migraine drugs189
The KRAS crowd targets its next cancer mutations182
Nanoparticle chirality sets the dial on immunogenicity181
mRNA-encoded monoclonal antibody fights CHIKV162
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval158
FDA new drug approvals in Q1 2023154
Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease152
Epigenetic editor silences prion protein151
Comprehensive measurement of biopharmaceutical R&D investment151
New naming scheme for antibodies drops the -mab stem150
Comparing development strategies for PD1/PDL1-based immunotherapies147
Understanding the effects of antibiotic combinations143
Top companies and drugs by sales in 2020126
Therapeutic RNA-silencing oligonucleotides in metabolic diseases125
Targeting tumour N-glycosylation123
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion122
Ipsen buys Epizyme for US$247 million116
Promoting tissue repair after heart attack114
Weeding out toxic RNA in Huntington disease113
Pasting in large DNA sequences112
Understanding long-lasting ketamine effects108
Targeting tumour-associated bacteria104
Bacteria tag tumours for CAR-T cell attack103
FDA new drug approvals in Q1 202199
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer98
The improving benefit–risk balance of phase I cancer trials94
A specific biomarker for insoluble tau89
Vaccine exposes tumours to immune cell attack87
Improving circular RNA protein yields87
Pfizer buys Biohaven’s migraine drugs for $11.6 billion81
Neutralizing Zika virus80
Upcoming market catalysts in Q1 202380
Upcoming market catalysts in Q3 202280
0.041079044342041